BIOAGE Labs

BIOAGE Labs EBIT Margin

The EBIT Margin (Operating Margin) of BIOAGE Labs (BIOA) as of Oct 22, 2026 is -1,031.46 %. In the previous year, EBIT Margin (Operating Margin) was -736.22 % — a change of 40.10% (lower).

EBIT Margin

-1,031.46 %

YoY

40.10%

Last updated:

EBIT Margin (Operating Margin) of BIOAGE Labs is 2025 -1,031.46 % . EBIT Margin (Operating Margin) of BIOAGE Labs was 2024 -736.22 % . It decreases by 40.10% lower compared to the previous year.

BIOAGE Labs's operating (EBIT) margin stands at -1,031.5%, up from -2,281.5% several years earlier.

The BIOAGE Labs EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2013
-15.45 USD
Jan 1, 2014
-2,281.51 USD
Jan 1, 2015
-1,773.92 USD
Jan 1, 2016
-358.17 USD
Jan 1, 2017
-736.22 USD
Jan 1, 2025
-1,031.46 USD
The BIOAGE Labs EBIT Margin history
YEAREBIT MarginYoY
-1,031.46 %+40.10%
-736.22 %+105.55%
-358.17 %-79.81%
-1,773.92 %-22.25%
-2,281.51 %+14,666.35%
-15.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BIOAGE Labs Stock analysis

What does BIOAGE Labs do? BIOAGE Labs Inc generates revenue through the development and potential commercialization of therapeutic product candidates for metabolic diseases. Its lead product azelaprag, an orally available small molecule agonist of the apelin receptor, is being tested in a Phase II trial combined with tirzepatide for obesity treatment in older adults. The company also develops NLRP3 inhibitors as preclinical programs targeting neuroinflammation-driven diseases. BIOAGE Labs focuses on clinical-stage biopharmaceutical development for metabolic aging pathways, with products targeting obesity therapy and body composition improvement in patients using incretin drugs. The company's primary market segments include patients with obesity requiring treatment, particularly older adults, and those needing therapies addressing neuroinflammation. BIOAGE Labs targets healthcare providers and pharmaceutical partners interested in metabolic disease treatments and neuroinflammation therapies. The company's products are developed for clinical use rather than direct consumer sales, with revenue anticipated from future partnerships or product sales upon successful clinical trials and regulatory approvals. BIOAGE Labs' business model centers on advancing its pipeline of therapeutic candidates through clinical trials, leveraging its discovery platform built on human longevity data. The company's focus on metabolic aging pathways and its lead candidate azelaprag for obesity treatment in combination with incretin drugs like tirzepatide positions it within the pharmaceutical industry. The company's preclinical programs for NLRP3 inhibitors represent additional potential revenue streams once development progresses to clinical stages. BIOAGE Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BIOAGE Labs stock

EBIT Margin (Operating Margin) of BIOAGE Labs is -1,031.46 % in 2025.

EBIT Margin (Operating Margin) of BIOAGE Labs changed from -736.22 % to -1,031.46 %, representing a 40.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) BIOAGE Labs since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s BIOAGE Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — BIOAGE Labs

All Key Metrics — BIOAGE Labs